Research Article

Effect of Certain Oral Anti Diabetic Drugs on Coagulation Cascade in Diabetes Mellitus

Patil T R[1*], Patil S T[2] , Patil S[3], Patil A[4]

[1]Department of Pharmacology, Bharati Medical College and Hospital, Sangli, Maharashtra, India
[2]Gynecologist, Private Practice, Miraj, Maharashtra, India
[3]Department of Public Health Dentistry, School of Dental Sciences, Karad, Maharashtra, India
[4]MDS, Oral pathologist, Private Practice, Miraj, Maharashtra, India

ABSTRACT

Thrombotic events in diabetics contribute for almost 65-80% of cardiovascular events. Diabetes affects the platelet, the coagulation factors and fibrinolytic system leading to a state of hypercoagulation and hypofibrinolysis resulting in to thrombosis. Oral drugs commonly used in management of type II diabetes mellitus are antidiabetics like metformin, PPAR-γ agonist and DPP-4 inhibitor. They rarely produce hypoglycemia. Metformin has been proved to prevent release of mtDNA from arachidonic acid stimulated platelets, reduce membrane damage and mitochondrial ROS production in the platelets. Similarly processes like platelet adhesion, activation and aggregation on collagen coated surfaces which initiate thrombosis are prevented by metformin. PPAR- γ agonists like pioglitazone and rosiglitazone have anti atherogenic effect. They decrease the expression of inflammatory markers and affect the coagulation markers like factor VII: C and inhibit platelet activation. Pioglitazone also reduces the VLDL, triglycerides and increases HDL which further contributes in attenuation of atherosclerosis. DPP-4 inhibitors, which are relatively newer class of antidiabetics, having minimum potential for hypoglycemia induction, due to their novel mechanism of action. Studies have proved that long term use of DPP-4 inhibitors have reduced cardiac mortality by their lipid lowering action, increased release of NO from endothelium and inhibition of TNF- α, PAI-1 and VCAM expression. Increased levels of stromal cell derived factor - 1α helps to maintain endothelial homeostasis and vascular repair. Decreased oxidative stress, inhibition of inflammatory genes like IL-6, IL-12, TNF- α provide additional benefit. Destabilization of vasculo-atherosclerotic plaque is prevented by DPP-4 inhibitors. Thus these oral antidiabetics drugs offer many benefits beyond blood glucose control which prevent atherosclerosis, inhibits hypercoagulable state and enhances fibrinolysis which translates into decreased cardiac complications in diabetes.

Keywords: Oral Antidiabetics, Meformin, mtDNA.

INTRODUCTION

Diabetes mellitus has attained an epidemic proportion as number of diabetics is increasing world-wide. By the year 2025, it is estimated that 324 million population will be diabetic[1]. Morbidity and mortality in type 2 Diabetes mellitus arise from microvascular complications like nephropathy, neuropathy and retinopathy and macrovascular complications like coronary artery diseases, cerebrovascular strokes and peripheral artery disease[2-6]. Thrombotic events in diabetics contribute for almost 80% of cardiovascular events[7,8]. Hypercoagulability and hypofibrinolysis in diabetes mellitus correlate with vascular complications[2].

Endothelial changes in Diabetes Mellitus

The endothelium plays an important role in the prevention of intravascular coagulation through the generation of nitric oxide [NO], prostacycline and by stimulating tissue plasminogen activator and fibrinolytic system[9]. Endothelial dysfunction in diabetes mellitus, hypertension and hyperlipidemia triggers inflammatory process leading to atherosclerosis[10]. Diabetic hyperglycemia through the formation of advanced glycation end products (AGE's) injures endothelium by irreversible glycation of collagen and subendothelial proteins[11]. AGEs damage blood vessel basement membrane[12]. Levels of plasma thrombomodulin (TM) a membrane protein are increased in Type II diabetes mellitus and correlate with vascular injury[13-15]. Von willebrand factor (vWF), a glycoprotein synthesized by megakaryocytes and endothelial cells is increased in type II diabetes mellitus[16-18]. It is a marker of endothelial injury and bears a positive correlation with progressive micro and macro vascular complication in diabetes[15,16,19].

Diabetic dyslipidemia contributing to endothelial dysfunction possibly arises from difficulty in binding of lipoprotein lipase to an endothelium[20].

Platelet changes in Diabetes

Platelets form a plug as a reaction to endothelial injury through platelet aggregation, adhesion triggered by platelet aggregators like ADP, thromboxane and activation

of glycoprotein IIb/IIIa receptors which help the platelet binding with each other through fibrinogen[21,22]. Number of circulating platelets in DM patients remains unaffected[7]. The hyperglycemia induced osmotic effect in DM increases the platelet aggregation and degranulation[23]. Glycation of platelet membrane proteins increases platelet reactivity and number of GpIb, IIb and III a molecules and reduces the fluidity of the platelet membrane[24,25]. Increased platelet activation in type II diabetes mellitus is due to increased levels of markers of platelet activation stored in them like beta thromboglobulin and platelet factor IV in the plasma[10]. P-selectin on the platelet surface which is also a platelet activation marker, correlated to the thrombus formation and is found to be increased in diabetic patients[26]. Platelet plug gets supported by the formation of fibrin clot which helps to stop the bleeding[27].

Changes in coagulation factors

In type II diabetes mellitus patients, increased levels of factor VII is correlated to diabetic dyslipidemia. Factor VII circulates in the plasma bound to VLDL rich in triglycerides which results in to prolongation of the plasma half life of factor VII[10,16,28]. The factor VIII /vWF is increased in diabetes mellitus and in patients with insulin resistance as a result of endothelial dysfunction and inflammation[10,11,16].

About 95% of factor VIII which circulates in plasma is bound to vWF. Plasma levels of vWF are regulated by it's endothelial secretion and by TNF induced by inflammation[16]. Increased plasma levels of factor VIII is an independent risk factor for thromboembolism[29]. Another independent risk factor, fibrinogen for cardiovascular disorders is also increased in DM[11,16,20,28,30]. Hyperglycemia induced glycation of fibrinogen results into denser fibrin clot resistant to firbinolysis. The binding of the glycated fibrin is less to tissue type plasminogen activator resulting into reduced generation of plasmin and increased binding to α2 antiplasmin[7,10]. Prothrombin fragment 1 & 2, thrombin- antithrombin complex and fibrinopeptide which are the markers in hypercoagulability are found to be increased in diabetics[2,7,8,31,32].

Changes in natural anticoagulation in Diabetes Mellitus

Process of formation of thrombus is counter regulated by natural anticoagulants like 1) serine protease inhibitors such as antithrombin (AT), heparin co factor 2 and tissue factor pathway inhibitor (TFPI) and 2) inhibitors of activated protein C (PC) and its co factors protein S (PS)[33]. Decreased levels PC, PS and AT form the risk factors for thrombotic events[29]. In diabetics hyperglycemia results into decreased activity of AT which favours prothrombotic state[34-36].

Changes in fibrinolytic system

Hyperglycemia stimulates plasminogen activator inhibitor -1[PAI-1] production which favours the persistence of fibrin clot and development of thrombus[20,37,38]. Elevated levels of PAI-1 have also been considered as risk factor for the development of type II diabetes mellitus as they were found to be increased before the onset of type II diabetes mellitus[10].

Hypercoagulation and hypofibrinolytic state in diabetes favours thrombus formation as there was increase in the hypercoagulability markers such as fibrinopeptide A, prothrombin fragment 1 and 2, thrombin-anti thrombin complex, fibrinogen, soluble vWF, soluble thrombomodulin, D-diamer and PAI-1[11,13,15,27].

Type II diabetes mellitus initiates the process of endothelial dysfunction, atherosclerosis and vascular thrombotic complications[39-43]. Similarly, increased concentration of coagulation factors has been reported in type II diabetes mellitus.[39,44,45,46].

Coagulation factors VIII and its carrier vWF are increased in diabetics making them susceptible for myocardial infarction [MI][47,48]. Similarly, elevated levels of factor XI is known to be an independent risk factor for thrombotic complications like MI[49-58]. Hyperglycemia and hyperinsulinemia leads to increased activity of tissue factor [TF] and subsequent increase in coronary complications[39,54,59-63]. It activates coagulation pathway through activation of factor VII[41,64,65].

Hyperinsulinemia in diabetes mellitus impairs fibrinolysis even with the normal glucose concentration. Similarly hyperglycemia triggers coagulation which is unrelated to insulin concentration. Thus both hyperglycemia and hyperinsulinemia in type II diabetes mellitus have strong procoagulant effect by triggering coagulation machinery and simultaneous inhibition of fibrinolysis[66].

To summarize, in diabetics the atherosclerosis starts somewhat 20 years earlier as compared with non diabetics. Thrombotic complications constitute cerebrovascular events, coronary artery disease and peripheral vascular disease[67]. Imbalance between coagulation and fibrinolysis along with platelet dysfunction is responsible for thrombosis[68].

Hyperglycemia and insulin resistance in type II diabetes mellitus leads to enhanced platelet aggregation and increased levels of fibrinogen[69-71], vWF and PAI-1. Rise in levels of inflammatory markers like C-reactive protein, cytokines[71] and adhesion molecules[74,75] have been found to be elevated in type II diabetes Mellitus. In type II diabetes mellitus hyperglycemia initiates the problem of thrombogenesis through advanced glycation end products, endothelial dysfunction with decreased NO generation, enhanced platelet aggregation and inhibition of levels of PAI-1 and reduced levels of tissue plasminogen activation (t-PA)[119,120]. AGE increases oxidative stress resulting into endothelial dysfunction with increasing levels of CRP, IL-6, TNF-α, VCAM and ICAM[74,75]. Decreased NO generation adds to endothelial dysfunction. Elevated levels of inflammatory mediators, platelet aggregation and decreased PAI makes the atheromatous plaque unstable. Unstable plaque initiates the coagulation cascade by activating extrinsic factors like tissue factor and Factor VII and intrinsic factors like factor VIII,XI, XII[78]. Enhanced fibrinogen generation as a result of endothelial dysfunction, increased AGE's and heightened oxidative stress helps in clot formation along with plaque rupture and coagulation cascade. There are decreased levels of endogenous anticoagulants like anti thrombin III, protein C and thrombomodulin[71,79].

Type II diabetes mellitus respond therapeutically to oral drugs except where there is confirmed drug failure which

necessitates use of insulin. Available oral antidiabetic drugs are categorized as

Oral hypoglycemic drugs like sulphonylureas and meglitinides

Oral drugs which are antidiabetic and are rarely hypoglycemic e.g, biguanides like metformin, PPAR- γ agonists like thiazolidinediones (pioglitazone and rosiglitazone), DPP 4 inhibitors (siltagliptine)

Drugs which inhibit the intestinal absorption of glucose and are anti-hyperglycemics like α- glucosidase inhibitors

Sodium glucose transporter- 2 inhibitors (SGLT-2 inhibitors) – glucose excretion enhancers like canagliflozine.

Out of all these drugs biguanides, PPAR –γ agonists and DPP-4 inhibitors are preferred due to their antidiabetic action and lack of hypoglycemic potential.

Metformin

Thrombosis is a major cause of mortality and morbidity in diabetic patients with the incidence of 65%-80%[80-82]. Metformin is a preferred first line drug in type II diabetes mellitus and has been reported to reduce the diabetes related mortality arising out of thrombotic events[83-87].

Diabetes related hyperglycemia triggers mitochondrial hyperpolarization of platelets, increases generation of reactive oxygen species resulting into platelet activation. It has been observed that thrombosis and platelet activation is related to mitochondrial function[88-91]. It was found that changes in mitochondria activate the platelets and these platelets can release mitochondria[90,91].

Studies done by Xin G et al has shown that release of mitochondrial DNA [mtDNA] from activated platelets was decreased by metformin. It also inhibited release of mtDNA from arachidonic acid (AA) and thrombin activated platelets. It did not induce platelet apoptosis. Study results suggest that membrane damage of activated platelets was prevented by metformin along with lowering of lipid peroxidation activity arising out of excess load of ROS. Mitochondrial ROS production in platelets was reduced by metformin. The three important key indices of mitochondrial function like intracellular ATP level, mitochondrial routine respiration and level of hyperpolarization of mitochondrial membrane potential were improved in metformin treated ADP activated platelets. It also inhibited complex I activity of respiratory chain in platelet mitochondria[92].

The mitochondrial electron transport chain (ETC) forms an important target and regulates mitochondrial function which includes mitochondrial membrane potential, ROS and ATP levels. Metformin was found to lower mtDNA release from activated platelets, inhibit complex I in ETC and suppress the mitochondrial dysfunction. mtDNA was found to increase platelet aggregation and αIIbβ3 expression which were observed to be reduced by metformin[92].

Release of mtDNA from activated platelets can induce platelet activation possibly through DC-Sign pathway. The three key indicators of platelet activation like αIIbβ3, cytosolic calcium and p-selectin were decreased with metformin which was comparable with the effect of aspirin. Platelet adhesion, activation and aggregation on collagen coated surfaces which initiate thrombosis were also inhibited by metformin[92].

Indices of viscoelastic property of developing clot, thrombogenesis and platelet activation were significantly improved with metformin without influencing prothrombin time, activated partial thromboplastin time , fibrinogen , thrombin time , coagulation factors II,V, VII-XII . Platelet count was observed to be unaffected. Unlike current antithrombotic agents, metformin could prevent thrombotic events without increasing bleeding episodes[92]. Metformin did not have adverse effects of current antiplatelet agents like bleeding episodes, neutropenia, thrombocytopenia and gastrointestinal toxicities[93-95].

The mechanism for decreased ROS production in the platelets due to metformin did not involve NADPH peroxidase I. But metformin decreased ROS generation by inhibiting conversion of superoxide to H_2O_2 by superoxide dismutase. Superoxide dismutase plays an important role in the generation of superoxides[92].

Intracellular ATP levels, hyper polarization level of mitochondrial membrane potential and mitochondrial routine respiration which are the three key indices of mitochondrial function were found to be improved in ADP stimulated platelets with decreased mitochondrial complex I activity and resulted into inhibition of platelet ROS formation[92].

Metformin in low concentration protected the mitochondrial function and inhibited mtDNA release. mtDNA released from activated platelets acts as agonist for platelet activation and thrombosis. mtDNA also plays important role in immune and inflammatory responses and diseases arising out of it[96-100]. Aspirin is most commonly used anti platelet drug to prevent thrombotic episodes in diabetics. But 10-40% of diabetic patients are found to have biochemical resistance to this drug. Hence, newer therapies which can target underlying platelet dysfunction deserve further exploration[101-103,80]. Hence, metformin forms a promising new class of antiplatelet drug in the inhibition of platelet activation and prevention of thrombotic episodes. Platelets are known to play major role in inflammatory and infectious diseases. It is known that bacterial infections are also the predisposing factors for atherosclerosis and thrombosis[104].

Imbalance between the clot formation and its lysis results into vessel occlusion. Augmentation of fibrinolytic process has an impact on clot dissolution. Metformin has shown mild decrease in cholesterol and fibrinogen with increased fibrinolytic activity as monitored by euglobulin clot lysis time. There was fall in the fibrinolytic inhibitor, PAI-1[105-111].

This response was independent of dosage[111]. Use of metformin was found to be associated with the reduction in coagulation factor VII levels[112] and also the levels of Factor XIII and Factor XIIIA and B sub-unit in the plasma. It also affected fibrin polymerization and its aggregation[113]. The cross linking of fibrin and formation of advanced glycation end products both share common amino acid interaction which is likely to get interrupted by metformin[114].

Type II diabetes patients when treated with metformin were found to have reduced markers of platelet activation like platelet factor IV and beta thromboglobulin resulting in to platelet stabilization[115]. Metformin is also known to exert antioxidant effect on the platelets[116].

Metformin was also found to have action on blood flow in type II diabetes mellitus patients. Patients of type II diabetes Mellitus when treated with metformin for six months were found to have increased hemodynamic response to L-arginine which is a precursor of nitric oxide[117]. It also lowered the levels of ADMA[118]. There was improved blood flow both in skeletal muscles and adipose tissue[119].

The results of UKPDS study conducted in overweight type II diabetics showed reduced cardiovascular mortality in them with metformin as compared to insulin or sulphonylureas, despite similar improvement in glycemic control[120].

Activated partial thromboplastin time which reflects the function of intrinsic system of coagulation cascade was affected insignificantly by metformin and also the INR, which is a parameter of activity of extrinsic pathway of coagulation[121]. But fibrinogen and PAI-1 were affected significantly by metformin[122].

PPAR γ- agonist thiozolidinediones- glitazone -TZDs

Pioglitazone and rosiglitazone are currently used PPAR γ agonists. They are insulin sensitizers and reduce the cardiovascular risk in type II diabetes mellitus[123].

They have antiatherogenic effect and also have been observed to affect coagulation cascade favourably and maintain vascular homeostasis beyond their antidiabetic effect[124-126]. Their antiatherogenic effect in type II diabetes Mellitus is attributed to their insulin sensitization potential, lowering of blood sugar, decrease in LDL and triglyceride level. Lowering of vascular monocytes and T cell recruitment, decrease in T cell activation and vascular smooth muscle cell [VSMC] migration in the formation of foam cells also contribute to this effect. They also reduce inflammatory biomarkers in the atheromatous plaque[127-128].

By decreasing expression of inflammatory markers and adhesion molecules like VCAM, pioglitazone improved endothelial function and release of NO, and decreased oxidative stress and CRP levels[129-133]. VSMC accelerates the atherosclerosis through accretion of lipid plaque, generation of extracellular matrix and by release of inflammatory cytokines[134]. Pioglitazone reduces VSMC cell migration, proliferation and enhances their apoptosis[135].

Pioglitazone was found to affect coagulation markers like Factor VII:C, VII: Ag, PAI-1 and vWF in type II diabetes mellitus[126,136]. Platelet activation was also observed to be inhibited[137,138]. TNF α mediated stimulation of PAI-1 was seen to be inhibited by both pioglitazone and rosiglitazone[139].

Circulating levels of biomarkers of inflammation and coronary atherosclerosis like CRP, adiponectin, PAI-1 and monocytes chemoreactant protein- 1[MCP-1] a chemokine which regulate migration and infiltration of monocyte/macrophagess and matrix metallopeptidase[MMP-9] which is involved in degradation of extracellular matrix are also reduced by pioglitazone. Pioglitazone directly affect VSMC , endothelial cells and ratio of macrophages/monocytes which plays an important role in the process of atherosclerosis. Pioglitazone is known to influence vWF by affecting its expression from monocytes which also play an important role in the process of atherosclerosis and coagulation[140].

Endothelial dysfunction is improved by inhibiting endothelial cell inflammation and monocytes adhesion by inhibiting VCAM-1 expression on activated endothelial cell by pioglitazone. It also reduces TNF- alpha induced RAGE expression by inhibiting NFkB, an important pro inflammatory transcription factor[141,135].

Human bone marrow megakaryocytes and platelets express PPAR- γ receptors and PPAR- γ agonist inhibit release of thromboxane and inhibit platelet aggregation. PPAR- γ agonist like TZDS forms the target for antiplatelet therapy[138].

Rosiglitazone also has been found to inhibit PAI-1[126].

Dipeptidyl peptidase 4-[DPP-4] inhibitors

DPP-4 inhibitors like sitagliptine, vildagliptine are antidiabetic drugs used in type II diabetes mellitus. They are found to decrease total cholesterol, LDL and triglycerides and increase high density lipoprotein cholesterol[142]. They have additional cardioprotective effect beyond the glucose control[143,144]. They act through GLP-1 receptors located on endothelium and smooth muscle cells in blood vessels[144]. GLP 1 receptor stimulation in endothelium helps to generate vasorelaxant and antiplatelet NO by drugs like sitagliptine. Inhibition of TNF-α, PAI-1 and VCAM expression was observed with liraglutide[143].

The cytokines and chemokines play an important role in thrombogenesis. Their levels were found to be affected by DPP-4 inhibitors. Stromal cell derived factor -1 α (SDF-1 α) levels are increased by DPP4 inhibitors resulting into stimulation of endothelial progenitor cells (EPCS) helping to maintain endothelial homeostasis and vascular repair. Proinflammatory chemokines like MCP-1 regulate homing of activated monocytes into atherosclerotic plaque. Sitagliptine therapy reduced the levels of MCP-1 and enhanced the levels of SDF-1α and EPCs[145].

NFkB regulates proinflammatory genes and proliferation of VSMCs which play an important role in atherogenesis[146]. DPP-4 inhibition leads to NFkB activation in T cells interacting with caspase recruitment domain family member 11 (CARD-11)[147].

Treatment with DPP-4 inhibitor, vildagliptine resulted into reduced oxidative stress and inhibition of inflammatory, thrombogenic and fibrotic gene expression like ICAM-1, PAI-1 and tissue growth factor in animal models of diabetes[148].

Sitagliptine was found to reduce mRNA expression of inflammatory genes like IL-6, IL-12 and TNF α in adipose tissues and IL-6 and IL 1 and MCP 1 in endocrine glands. Activation of MMPs through toll like receptor pathway plays an important role in destabilization of atherosclerotic

plaque resulting into acute vascular event. DPP-4 inhibitors are shown to prevent activation of MMPs[145]. Alogliptine enhanced the release of NO in cultured endothelial cells via activation of the Akt-eNOS pathway and produce vasorelaxation. GLP-1 stimulation itself stimulates generation of NO through eNOS[145].

CONCLUSION

The epidemic of type II diabetes mellitus is threatening human health not only due to hyperglycemia but also due to vasculo-thrombotic events in the vital organs like heart, brain, kidney. Hence it becomes imperative to choose the oral antidiabetic drug which not only should control hyperglycemia but also offer protection against microvascular, macrovascular pathologies and thromboembolic complications. Amongst the oral antidiabetic drugs, biguanides, thiozolidinediones and DPP-4 inhibitors are the promising agents in the prevention of these vascular complications by various mechanisms which inhibit hypercoagulable state and accelerate fibrinolysis. Reduced platelet aggregation, enhanced fibrinolysis and reduced fibrin generation, inhibition of PAI-1, correction of hyperlipidemia, inhibition of inflammatory mediators and generation of ROS and regression of atherosclerosis are the prominent mechanisms through which these drugs can fulfill these goals. Inhibition of platelet mtDNA released by metformin if properly investigated can prove it to be a new antiplatelet agent. Lack of its hypoglycemic potential would facilitate its use in nondiabetic conditions as antiplatelet agent. Emerging resistance to antiplatelet drug aspirin to the tune of 40% compels to consider metformin as antiplatelet drug in type II diabetes.

REFERENCES

1. Cheng D. Prevalence, predisposition and prevention of type II diabetes. Nutr Metab (Lond). 2005;2:29.
2. Yamada T, Sato A, Nishimori T, Mitsuhashi T, Terao A, Sagai H, et al. Importance of hypercoagulability over hyperglycemia for vascular complication in type 2 diabetes. Diabetes Res Clin Pract. 2000;49(1):23-31.
3. Nazimek-Siewniak B, Moczulski D, Grzeszczak W. Risk of macrovascular and microvascular complications in Type 2 diabetes: results of longitudinal study design. J Diabetes Complications. 2002;16(4):271-6.
4. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414(6865):813-20. 6.
5. Fuller JH, Stevens LK, Wang SL. Risk factors for cardiovascular mortality and morbidity: the WHO Mutinational Study of Vascular Disease in Diabetes. Diabetologia. 2001;44 Suppl 2:S54-64. 7.
6. Bennett PH, Lee ET, Lu M, Keen H, Fuller JH. Increased urinary albumin excretion and its associations in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 2001;44 Suppl 2:S37-45.
7. Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications. 2001;15(1):44-54.
8. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. 2001;37(4):1053- 9. Erratum in: Hypertension 2001;37(5):1350. Comment in: Hypertension. 2001;38(3):E11.
9. van Hinsberg VW. The endothelium: vascular control of haemostasis. Eur J Obstet Gynecol Reprod Biol. 2001;95(2):198- 201.
10. Grant PJ. Diabetes melito as a prothrombotic condition. J Intern Med. 2007;262(2):157-72.
11. Meigs JB, Mittleman MA, Nathan DM, Tofler GH, Singer DE, Murphy-Sheehy PM, et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA. 2000;283(2):221-8.
12. Tooke JE. Microvascular function in human diabetes. A physiological perspective. Diabetes. 1995;44(7):721-6. Review.
13. Aso Y, Fujiwara Y, Tayama K, Takebayashi K, Inukai T, Takemura Y. Relationship between soluble thrombomodulin in plasma and coagulation or fibrinolysis in type 2 diabetes. Clin Chim Acta. 2000;301(1-2):135-45.
14. Weiler H, Isermann BH. Thrombomodulin. J Thromb Haemost. 2003;1(7):1515-24. Review.
15. Hirano T, Ookubo K, Kashiwazaki K, Tajima H, Yoshino G, Adachi M. Vascular endothelial markers, von Willebrand factor and thrombomodulin index, are specifically elevated in type 2 diabetic patients with nephropathy: comparison of primary renal disease. Clin Chim Acta. 2000;299(1-2):65-75.
16. Duncan BB, Schmidt MI, Offenbacher S, Wu KK, Savage PJ, Heiss G. Factor VIII and other hemostasis variables are related to incident diabetes in adults. The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care. 1999;22(5):767-72.
17. Reininger AJ. VWF attributes—impact on thrombus formation. Thromb Res. 2008;122 Suppl 4:S9-13.
18. Meigs JB, O'donnell CJ, Tofler GH, Benjamin EJ, Fox CS, Lipinska I, et al. Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study. Diabetes. 2006;55(2):530-7
19. Blann AD, Lip GY. The endothelium in atherothrombotic disease: assessment of function, mechanisms and clinical implications. Blood Coagul Fibrinolysis. 1998;9(4):297-306.
20. Yudkin JS. Abnormalities of coagulation and fibrinolysis in insulin resistance. Evidence for a common antecedent? Diabetes Care. 1999;22 Suppl 3:C25-30.
21. Steen VM, Holmsen H. Current aspects on human platelet activation and responses. Eur J Haematol. 1987;38(5):383-99.
22. Kottke-Marchant K, Corcoran G. The laboratory diagnosis of platelet disorders. Arch Pathol Lab Med. 2002;126(2):133-46.
23. Keating FK, Sobel BE, Schneider DJ. Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and

without diabetes mellitus. Am J Cardiol. 2003;92(11):1362-5.

24. Winocour PD. Platelets, vascular disease, and diabetes mellitus. Can J Physiol Pharmacol. 1994;72(3):295-303. Review.

25. Kühne T, Hornstein A, Semple J, Chang W, Blanchette V, Freedman J. Flow cytometric evaluation of platelet activation in blood collected into EDTA vs. Diatube-H, a sodium citrate solution supplemented with theophylline, adenosine, and dipyridamole. Am J Hematol. 1995;50(1):40-5. Comment in: Am J Hematol. 1997;54(4):343-4.

26. Ouviña SM, La Greca RD, Zanaro NL, Palmer L, Sassetti B. Endothelial dysfunction, nitric oxide and platelet activation in hypertensive and diabetic type II patients. Thromb Res. 2001; 102(2):107-14.

27. Lind SE, Marks PW, Ewenstein BM. Hemostatic system. In: Lux SE, Stossel TP, Handin RI. Blood: principles and practice of Hematology. 2° ed. Lippincott: Williams & Wilkins; 2003. Chapter 31. p. 959-982

28. Juhan-Vague I, Alessi MC, Vague P. Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. Ann Med. 1996;28(4):371-80.

29. Tripodi A, Mannucci PM. Laboratory investigation of thrombophilia. Clin Chem. 2001;47(9):1597-606.

30. Weisel JW, Grant PJ. Biology and disorders of fibrinogen and factor XIII. In: Lux SE, Stossel TP, Handin RI. Blood: principles and practice of Hematology. 2° ed. Lippincott: Williams & Wilkins; 2003. Chapter 39. p. 1225-1248.

31. Mykkanen L. Prevention of coronary heart disease in type 2 diabetes. Int J Clin Pract Suppl. 2000;(113):40-5. Review

32. Sumpio BE, Riley JT, Dardik A. Cells in focus: endothelial cell. Int J Biochem Cell Biol. 2002;34(12):1508-12.

33. Dahlback B. Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases. J Intern Med. 2005;257(3):209-23.

34. Kozek E, Katra B, Malecki M, Sieradzki J. Visceral obesity and hemostatic profile in patients with type 2 diabetes: the effect of gender and metabolic compensation. Rev Diabet Stud. 2004;1 (3):122-8

35. Villanueva GB, Allen N. Demonstration of altered antithrombin III activity due to nonenzymatic glycosylation at glucose concentration expected to be encountered in severely diabetic patients. Diabetes. 1988;37(8):1103-7.

36. Ceriello A, Giugliano D, Quatraro A, Consoli G, Stante A, Dello Russo P, et al. Induced hyperglycemia alters antithrombin III activity but not its plasma concentration in healthy normal subjects. Diabetes. 1987;36(3):320-3.

37. Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen

38. Lijnert RG, Collen D. Fibrinolytic system and its disorders. In: Lux SE, Stossel TP, Handin RI. Blood: principles and practice of Hematology. 2° ed. Lippincott: Williams & Wilkins; 2003. Chapter 40. p. 1249-1274.

39. Hagracy RS, Kamal GM, Sabry IM, Saad AA, Abou El Ezz NF, Nasr HA. Tissue Factor, Tissue Factor Pathway Inhibitor and Factor VII Activity in Cardiovascular Complicated Type 2 Diabetes Mellitus. Oman Med J. 2010; 25(3):173-8. PMID: 22043333

40. Paoletti R, Bolego C, Poli A, Cignarella A. Metabolic syndrome, inflammation and atherosclerosis. Vasc Health Risk Manag. 2006; 2(2):145-52.

41. Gentile NT, Vaidyula VR, Kanamalla U, DeAngelis M, Gaughan J, Rao AK. Factor VIIa and tissue factor procoagulant activity in diabetes mellitus after acute ischemic stroke: impact of hyperglycemia. Thromb Haemost. 2007; 98(5):1007-1013.

42. Carr ME. Diabetes mellitus: a hypercoagulable state. Hamsten A,J Diabetes Complications. 2001; 15(1):44-54.

43. Bogdanov VY, Osterud B. Cardiovascular complications of diabetes mellitus: The Tissue Factor perspective. Thromb Res. 2010; 125(2):112-8.

44. Arbustini E, Narula N, D'Armini AM. Fibrinogen: a circulating factor in search of its genetic architecture. Circulation. 2013, 128(12):1276-80.

45. Fujii T, Saito S. Hemostatic treatment for in tractable traumatic hemorrhage using fibrinogen concentrates and recombinant activated factor VII. Rinsho Ketsueki. 2014, 55(2):234-8.

46. de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update. Semin Thromb Hemost. 2013, 39(6):585-95.

47. Nossent AY, Ellenbroek JH, Frölich M, Bertina RM, Knoers NV, Eikenboom JC. Plasma levels of von Willebrand factor, von Willebrand factor propeptide and factor VIII in carriers and patients with nephrogenic diabetes insipidus. Thromb Res. 2010; 125(6):554-6.

48. Karabuva S, Carević V, Radić M, Fabijanić D. The association of ABO blood groups with extent of coronary atherosclerosis in Croatian patients suffering from chronic coronary artery disease. Biochem Med (Zagreb). 2013;23(3):351-9.

49. Tanis B, Algra A, van der Graaf Y, Helmerhorst F, Rosendaal F. Procoagulant factors and the risk of myocardial infarction in young women. Eur J Haematol. 2006 Jul;77(1):67-73.

50. Kalani M, Silveira A, Blombäck M, Apelqvist J, Eliasson B, Eriksson JW, Fagrell B, Torffvit O, Hamsten A, Jörneskog G. Beneficial effects of dalteparin on haemostatic function and local tissue oxygenation in patients with diabetes, severe vascular disease and foot ulcers. Thromb Res. 2007; 120(5):653-61.

51. Mogielnicki A, Kramkowski K, Hermanowicz JM, Leszczynska A, Przyborowski K, Buczko W. Angiotensin-(1-9) enhances stasis-induced venous thrombosis in the rat because of the impairment of fibrinolysis. J Renin Angiotensin Aldosterone Syst. 2014, 15(1):13-21.

52. Cristiani A, Vettore S, Sambado L, Bulfone A, Moro S, Girolami A. Conformational Changes of Congenital FVII Variants with Defective Binding to Tissue Factor ARG304GLN (FVII Padua), ARG 304TRP (FVII Nagoya) and ARG79GLN (FVII Shinjo or Tondabayashi). Int J Biomed Sci. 2013, 9(4):185-93.

53. Kong M, Kim Y, Lee C. Functional investigation of a venous thromboembolism GWAS signal in a promoter region of coagulation factor XI gene. Mol Biol Rep. 2014, 41(4):2015-9

54. Alexandru N, Jardín I, Popov D, Simionescu M, García-Estañ J, Salido GM, Rosado JA. Effect of homocysteine on calcium mobilization and platelet function in type 2 diabetes mellitus. J Cell Mol Med. 2008 Oct; 12(5B):2015-26.

55. Teligui L, Dalmayrac E, Mabilleau G, Macchi L, Godon A, Corbeau JJ, Denommé AS, Bouquet E, Boer C, Baufreton C. An ex vivo evaluation of blood coagulation and thromboresistance of two extracorporeal circuit coatings with reduced and full heparin dose. Interact Cardiovasc Thorac Surg. 2014 Mar 14. [Epub ahead of print]

56. Kim JH, Bae HY, Kim SY. Clinical marker of platelet hyperreactivity in diabetes mellitus. Diabetes Metab J. 2013, 37(6):423-8.

57. Kaur J. A Comprehensive Review on Metabolic Syndrome. Cardiol Res Pract. 2014;2014:943162.

58. Zhang Q, Ran X, Wang DW. Relation of plasma tissue kallikrein levels to presence and severity of coronary artery disease in a chinese population. PLoS One. 2014 Mar 13; 9(3):e91780.

59. Davidson L, Wilcox J, Kim D, Benton S, Fredi J, Vaughan D. Clinical features of precocious acute coronary syndrome. Am J Med. 2014 Feb; 127(2):140-4.

60. Van Dreden P, Hue G, Dreyfus JF, Woodhams B, Vasse M5. Procoagulant phospholipids and tissue factor activity in cerebrospinal fluid from patients with intracerebral haemorrhage. Adv Hematol. 2014:576750.

61. Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol. 2004; 24(6):1015-22.

62. Del Turco S, Basta G, Lazzerini G, Chancharme L, Lerond L, De Caterina R. Involvement of the TP receptor in TNF-α-induced endothelial tissue factor expression. Vascul Pharmacol. 2014, pii: S1537-1891(14)00060-3.

63. Gerrits AJ, Koekman CA, van Haeften TW, Akkerman JW. Platelet tissue factor synthesis in type 2 diabetic patients is resistant to inhibition by insulin. Diabetes. 2010; 59(6):1487-95.

64. Derosa G, D'Angelo A, Tinelli C, Devangelio E, Consoli A, Miccoli R, Penno G, Del Prato S, Paniga S, Cicero AF. Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects. Diabetes Metab. 2007; 33(2):129-34.

65. Turu MM, Krupinski J, Catena E, Rosell A, Montaner J, Rubio F, Alvarez-Sabin J, Cairols M, Badimon L. Intraplaque MMP-8 levels are increased in asymptomatic patients with carotid plaque progression on ultrasound. Atherosclerosis. 2006; 187(1):161-9.

66. Stegenga M, van der Crabben S, Levi M, de Vos A, Tanck M, Sauerwein H, van der Poll T. Hyperglycemia Stimulates Coagulation, Whereas Hyperinsulinemia Impairs Fibrinolysis in Healthy Humans. Diabetes 2006 Jun; 55(6): 1807-1812.

67. American Diabetes Association. Consensus statement role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. Diabetes Care 1989;12:573-9

68. Gough SCL, Grant PJ. The fibrinolytic system in diabetes mellitus. Diabetic Med 1991;8:898-905

69. Folsom AR, Conlan MG, Davis CE, et al. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Relations between hemostasis variables and cardiovascular risk factors in middle-aged adults. Ann Epidemiol 1992;2:481-94

70. Duncan BB, Schmidt MI, Offenbacher S, et al. The Atherosclerosis Risk in Communities (ARIC) Study, Factor VIII and other hemostasis variables are related to incident diabetes in adults. Diabetes Care 1999;22:767-72

71. Asakawa H, Tokunaga K, Kawakami F. Elevation of fibrinogen and thrombin-antithrombin III complex levels of type 2 diabetes mellitus patients with retinopathy and nephropathy. J Diabetes Complications 2000;14:121-6

72. Kwaan HC, Colwell JA, Cruz S, et al. Increased platelet aggregation in diabetes mellitus. J Lab Clin Med 1972;80:236-46

73. Vlassara H, Brownlee M, Manogue KR, et al. Cachectin/TNF and IL-1 induced by glucose-modified proteins; role in normal tissue remodeling. Science 1988;240:1546-8

74. Ford ES. Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care 1999;22:1971-7 24.

75. Salmi M, Stolen C, Jousilahti P, et al. Insulin-regulated increase of soluble vascular adhesion protein-1 in diabetes. Am J Pathol 2002;161:2255-62

76. Festa A, Agostino R, Mykkanen L, et al. The Insulin Resistance Atherosclerosis Study (IRAS). Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. Arterioscler Thromb Vasc Biol 1999;19:562-8 43.

77. Pandolfi A, Cetrullo D, Polishuck R, et al. Plasminogen activator inhibitor type 1 is increased in the arterial wall of type II diabetic subjects. Arterioscler Thromb Vasc Biol 2001;21:1378-82

78. Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications 2001;15:44-54 .. Study demonstrating hypercoagulation in diabetes

79. Salomaa V, Matei C, Aleksic N, et al. Atherosclerosis Risk in Communities. Cross-sectional association of soluble thrombomodulin with mild peripheral artery disease; the ARIC study. Atherosclerosis 2001;157:309-14.

80. Creager, M. A., Lüscher, T. F., Cosentino, F. & Beckman, J. A. Diabetes and Vascular Disease Pathophysiology, Clinical Consequences, and Medical Therapy: Part I. Circulation 108, 1527–1532 (2003).

81. Vazzana, N., Ranalli, P., Cuccurullo, C. & Davì, G. Diabetes mellitus and thrombosis. Thromb. Res. 129, 371–377 (2012).

82. Randriamboavonjy, V. et al. Metformin reduces hyper-reactivity of platelets from patients with polycystic ovary syndrome by improving mitochondrial integrity. Thromb Haemost. 114, 569–578 (2015)

83. Inzucchi, S. E. Metformin and heart failure. Diabetes Care. 28, 2585–2587 (2005).

84. Roussel, R. et al. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch. Intern. Med. 170, 1892–1899 (2010).

85. Madiraju, A. K. et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 150, 542–546 (2014).

86. Lu, D. Y. et al. Metformin use in patients with type 2 diabetes mellitus is associated with reduced risk of deep vein thrombosis: a non-randomized, pair-matched cohort study. BMC Cardiovasc Disord. 14, 187 (2014).

87. DeFronzo, R. A. et al. Effects of exenatide (Exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 28, 1092–1100 (2005)

88. Barile, C. J. et al. Inhibiting platelet-stimulated blood coagulation by inhibition of mitochondrial respiration. PNAS USA 109, 2539–2543 (2012).

89. Yamagishi, S. I., Edelstein, D., Du, X. L. & Brownlee, M. Hyperglycemia potentiates collagen-induced platelet activation through mitochondrial superoxide overproduction. Diabetes 50, 1491–1494 (2001).

90. Cardenes, N. et al. Platelet bioenergetic screen in sickle cell patients reveals mitochondrial complex V inhibition, which contributes to platelet activation. Blood 123, 2864–2872 (2014).

91. Boudreau, L. H. et al. Platelets release mitochondria serving as substrate for bactericidal group IIA-secreted phospholipase A2 to promote inflammation. Blood 124, 2173–2183 (2014).

92. Xin G, Wei Z, Ji C, Zheng H, Gu J, Ma L et al. Metformin Uniquely Prevents Thrombosis by Inhibiting Platelet Activation and mtDNA Release. Scientific Reports 6, Article number: 36222 (2016)

93. Musumeci, L. et al. Dual-specificity phosphatase 3 deficiency or inhibition limits platelet activation and arterial thrombosis. Circulation 131, 656–668 (2015).

94. Dayal, S. et al. Hydrogen peroxide promotes aging-related platelet hyperactivation and thrombosis. Circulation 127, 1308–1316 (2013).

95. Zhou, Q. et al. Ginsenoside Rg1 inhibits platelet activation and arterial thrombosis. Thromb Res. 133, 57–65 (2014).

96. Ballinger, S. W. et al. Hydrogen peroxide and peroxynitrite-induced mitochondrial DNA damage and dysfunction in vascular endothelial and smooth muscle cells. Circ Res. 86, 960–966 (2000)

97. Qin, C. et al. Variation of perioperative plasma mitochondrial DNA correlate with peak inflammatory cytokines caused by cardiac surgery with cardiopulmonary bypass. J Cardiothorac Surg. 10, 85 (2015).

98. Lal, I., Dittus, K. & Holmes, C. E. Platelets, coagulation and fibrinolysis in breast cancer progression. Breast Cancer Res. 15, 207 (2013).

99. West, A. P. et al. Mitochondrial DNA stress primes the antiviral innate immune response. Nature 520, 553–557 (2015).

100. Fitzgerald, J. R., Foster. T. J. & Cox, D. The interaction of bacterial pathogens with platelets. Nat Rev Microbiol. 4, 445–457 (2006).

101. Cho, N. H. et al. The IDF Diabetes Atlas 7th edition (2015).

102. Mackman, N. Triggers, targets and treatments for thrombosis. Nature 451, 914–918 (2008).

103. Tang, W. H. et al. Aldose reductase-mediated phosphorylation of p53 leads to mitochondrial dysfunction and damage in diabetic platelets. Circulation 129, 1598–1609 (2014).

104. Zhang, S. et al. Nucleotide-binding oligomerization domain 2 receptor is expressed in platelets and enhances platelet activation and thrombosis. Circulation 131, 1160–1170 (2015)

105. Hocking ED, Chakbarti R, Evans J, Fearnley GR. J Atheroscler Res. 1967 Mar-Apr;7(2):121-30. Effect of biguanides and atromid on fibrinolysis..

106. 63 Vague P, Juhan-Vague I, Alessi MC, Badier C, Valadier J. Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non-diabetic obese subjects. Thromb Haemost. 1987 Jun 3;57(3):326-8.

107. 65sadananda B, yesikar SS, Misra NP, Misra SM. Effect of metformin on fibrinolytic activity in diabetes mellitus. J. Diabet. Assoc. India 1974; 14: 33-38.

108. 66 Cho Y, Yang D, Oh D, Baick S, Kim S, Kim S, Hong S. Plasma t-PA and PAI-1 Antigen Concentrations in Non-Insulin Dependent Diabetic Patients: Effects of Treatment Modality on Fibrinolysis. Korean J Intern Med. 1992 Jul; 7(2): 81–86.

109. 67 Grant PJ, Stickland MH, Booth NA, Prentice CR. Metformin causes a reduction in basal and post-venous occlusion plasminogen activator inhibitor-1 in

type 2 diabetic patients. Diabet Med. 1991 May;8(4):361-5.

110. 68 Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care. 1993 Apr;16(4):621-9.

111. 69 Grant PJ. The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. Diabetes Care. 1996 Jan;19(1):64-6.

112. 70 Grant PJ. Metformin reduces circulating factor VII concentrations in patients with type 2 diabetes mellitus. Thromb Haemost. 1998 Jul;80(1):209-10.

113. 71 Standeven KF, Ariëns RA, Whitaker P, Ashcroft AE, Weisel JW, Grant PJ. The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation. Diabetes. 2002 Jan;51(1):189-97.\

114. 72 Tanaka Y, Iwamoto H, Onuma T, Kawamor R. Inhibitory effect of metformin on formation of advanced glycation end products. Current Therapeutic Research 1997; 58: 693-697.

115. 73 Gregorio F, Ambrosi F, Manfrini S, Velussi M, Carle F, Testa R, et al. Poorly controlled elderly Type 2 diabetic patients: the effects of increasing sulphonylurea dosages or adding metformin. Diabet Med. 1999 Dec;16(12):1016-24.

116. 74 Gargiulo P, Caccese D, Pignatelli P, Brufani C, De Vito F, Marino R et al. Metformin decreases platelet superoxide anion production in diabetic patients. Diabetes Metab Res Rev. 2002;18(2):156-9.

117. 77 Marfella R, Acampora R, Verrazzo G, Ziccardi P, De Rosa N, Giunta R et al. Metformin improves hemodynamic and rheological responses to L-arginine in NIDDM patients. Diabetes Care. 1996 Sep;19(9):934-9.

118. 78 Asagami T, Abbasi F, Stuelinger M, Lamendola C, McLaughlin T, Cooke JP, et al. Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism. 2002 Jul;51(7):843-6.

119. 79 Jansson PA, Gudbjörnsdóttir HS, Andersson OK, Lönnroth PN. The effect of metformin on adipose tissue metabolism and peripheral blood flow in subjects with NIDDM. Diabetes Care. 1996 Feb;19(2):160-4.

120. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):837-53.

121. Dahlback B: Blood coagulation. Lancet, 2000, 355, 1627–1632.

122. Krysiak R, Gdula-Dymek A, Okopień B. Effect of metformin on selected parameters of hemostasis in fenofibrate-treated patients with impaired glucose tolerance. Pharmacological Reports 2013, 65, 208-213.

123. Verges B. Clinical interest of PPARs ligands. Particular benefit in type 2 diabetes and metabolic syndrome. Diabetes Metab 2004;30:7-12.

124. Chu JW, Abbasi F, Lamendola C, et al. Effect of rosiglitazone on circulating vascular and inflammatory markers in insulin-resistant subjects. Diabetes Vasc Dis Res 2005;2:37-41.

125. Kruszynska YT, Yu JG, Olefsky JM, et al. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes 2000;49:633-9

126. Derosa G, Cicero AF, Gaddi A, et al. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Res Clin Pract 2005;69:5-13.

127. Gizard F, Bruemmer D. Transcriptional control of vascular smooth muscle cell proliferation by peroxisome proliferator-activated receptor-gamma: therapeutic implications for cardiovascular diseases. PPAR Res 2008;2008:429123

128. Elte JWF, Blickle JF. Reprint of: thiazolidinediones for the treatment of type 2 diabetes. Eur J Intern Med 2011;18(1):18-25

129. Pfutzner A, Marx N, Lubben G, et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 2005;45:1925-31.

130. Imamoto E, Yoshida N, Uchiyama K, et al. Inhibitory effect of pioglitazone on expression of adhesion molecules on neutrophils and endothelial cells. Biofactors 1920;1:37-47.

131. Polikandriotis JA, Mazzella LJ, Rupnow HL, Hart CM. Peroxisome proliferator-activated receptor gamma ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor gamma-dependent mechanisms. Arterioscler Thromb Vasc Biol 2005;25:1810-16.

132. Berhanu P, Kipnes MS, Khan MA, et al. Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy. Diab Vasc Dis Res 2006;3:39-44.

133. Szapary PO, Bloedon LT, Samaha FF, et al. Effects of pioglitazone on lipoproteins, inflammatory markers and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol 2006;26:182-8.

134. Doran AC, Meller N, McNamara CA. Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler Thromb Vasc Biol 2008;28:812-19

135. Aizawa Y, Kawabe J, Hasebe N, et al. Pioglitazone enhances cytokine-induced apoptosis in vascular smooth muscle cells and reduces intimal hyperplasia. Circulation 2001;104:455-60

136. Mieszczanska H, Kaba NK, Francis CW, Gerich JE, Dodis R, Schwarz KQ, et al. Effects of pioglitazone

on fasting and postprandial levels of lipid and hemostatic variables in overweight non-diabetic patients with coronary artery disease. J Thromb Haemost. 2007 May;5(5):942-9.

137. Borchert M, Schondorf T, Lubben G, et al. Review of the pleiotropic effects of peroxisome proliferatoractivated receptor gamma agonists on platelet function. Diabetes Technol Ther 2007;9:410-20

138. Akbiyik F, Ray DM, Gettings KF, et al. Human bone marrow megakaryocytes and platelets express PPARgamma, and PPARgamma agonists blunt platelet release of CD40 ligand and thromboxanes. Blood 2004;104(5):1361-8.

139. Liu HB, Hu YS, Medcalf RL, et al. Thiazolidinediones inhibit TNFalpha induction of PAI-1 independent of PPARgamma activation. Biochem Biophys Res Commun 2005;334:30-7

140. Blann AD, Lip GY. Effects of C-reactive protein on the release of von Willebrand factor, E-selectin, thrombomodulin and intercellular adhesion molecule-1 from human umbilical vein endothelial cells. Blood Coagul Fibrinolysis 2003;14:335-40

141. Kappert K, Meyborg H, Clemenz M, et al. Insulin facilitates monocyte migration: a possible link to tissue inflammation in insulin-resistance. Biochem Biophys Res Commun 2008;365:503-8

142. Rizzo M, Rizvi AA, Spinas GA, et al. Glucose lowering and antidiabetogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4

inhibitors. Expert Opin Investig Drugs 2009;18:1495-503

143. Anagnostis P, Athyros VG, Adamidou F, et al. Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes Obes Metab 2011;13:302-12

144. Ban K, Noyan-Ashraf MH, Hoefer J, et al. Cardioprotective and vasodilatory action of glucagon-like peptide1 receptor-dependent and independent pathways. Circulation 2008;117:2340-50

145. Fadini GP, Boscaro E, Albiero M, et al. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care 2010;33:1607-9

146. Sauve M, Ban K, Momen MA, et al. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes 2010;59:1063-73

147. Ohnuma K, Uchiyama M, Yamochi T, et al. Caveolin-1 triggers T-cell activation via CD26 in association with CARMA1. J Biol Chem 2007;282:10117-31

148. Yamagishi S, Maeda S, Matsui T. Vildagliptin inhibits oxidative stress and vascular damage in streptozotocin-induced diabetic rats. Int J Cardiol 2012;158(1):171-3